India Development News & Foreign Investment Opportunities

Dr. Reddy’s launches Carboprost Tromethamine Injection

FDA designate product as CGT


FDA designate product as CGT



Dr. Reddy’s Laboratories Ltd has announced the launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial, a therapeutic equivalent generic version of Hemabate® injection, 250 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA).

“We are pleased to be first-to-market with this product that has been designated as a Competitive Generic Therapy (CGT) by the FDA,” said Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories.

“With a CGT designation, we have 180-day CGT exclusivity to market this product,” he said announcing the product on 3 July 2019.

The Hemabate® injection, 250 mcg/mL brand had U.S. sales of approximately $55 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health*.

Dr. Reddy’s Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) contains carboprost tromethamine equivalent to 250 mcg of carboprost.

Leave A Reply

Your email address will not be published.